151751-Najiba-Chargi

233 Systemic therapy: skeletal muscle mass and bioradiotherapy 15. Williams BA, Mandrekar JN, Mandrekar SJ, et al. Finding Optimal Cutpoints for Contin- uous Covariates with Binary and Time-to- Event Outcomes .; 2006. 16. Chargi N, Bril SI, Emmelot-Vonk MH, de Bree R. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Oto-Rhi- no-Laryngology . 2019;276(5):1475-1486. doi:10.1007/s00405-019-05361-4 17. Sealy MJ, Dechaphunkul T, Van Der Schans CP, et al. Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. 2019. doi:10.1016/j. clnu.2019.02.029 18. Jung AR, Roh JL, Kim JS, et al. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer. Eur J Cancer . 2019;116:98-106. doi:10.1016/j.ejca.2019.05.006 19. Hilmi M, Jouinot A, Burns R, et al. Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology? 2018. doi:10.1016/j. pharmthera.2018.12.003 20. Zwart AT, Hoorn A, Ooijen PMA, Steen - bakkers RJHM, Bock GH, Halmos GB. CT ‐ measured skeletal muscle mass used to assess frailty in patients with head and neck cancer. J Cachexia Sarcopenia Muscle . 2019;10(5):1060-1069. doi:10.1002/ jcsm.12443 21. Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a Determinant of Che - motherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment. Clin Cancer Res . 2009;15(8):2920-2926. doi:10.1158/1078-0432.CCR-08-2242 22. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol . 2017;71:26-33. doi:10.1016/j.oraloncology.2017.05.012 23. Raafi Ali1 VEBMBSLBSREA, Caroline Mol- levi4 & Pierre Senesse2 5. Lean body mass as an independent determinant of dose-lim- iting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med . 2016;5(4):607-616. doi:10.1002/cam4.621 24. Pointreau Y, Azzopardi N, Ternant D, Calais G, Paintaud G. Cetuximab Pharmacokinet - ics Influences Overall Survival in Patients with Head and Neck Cancer. Ther Drug Monit . 2016;38(5):567-572. doi:10.1097/ FTD.0000000000000321 25. Marty E, Liu Y, Samuel A, Or O, Lane J. A review of sarcopenia: Enhancing aware- ness of an increasingly prevalent disease. Bone . 2017;105:276-286. doi:10.1016/j. bone.2017.09.008 12